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Abstract A series of potential biologically active 2-[3-
(4-phenyl-1-piperazinyl)propyl]-3-(4-substituted-benzoyl)-
4-hydroxy-2H-1,2-benzothiazine 1,1-dioxides was synthe-
sized in a straightforward manner by condensation of
respective 3-substituted-4-hydroxy-1,2-benzothiazine 1,
1-dioxides with 1-(1-chloropropyl)-4-phenylpiperazine.
The structures of all of the newly formed compounds were
identified by elemental analysis, FTIR and 1H NMR. The
synthesized compounds were subjected to preliminary
evaluation using differential scanning calorimetry (DSC) to
determine the existence of multiple crystal forms. The DSC
scans for all compounds show more than one endothermic
effect, which might suggest dynamic proton transfer between
two or three possible tautomeric forms: O-keto/O-enol,
O-enol/O-keto and O-keto/O-keto/CH2 in crystals 2-[3-
(4-phenyl-1-piperazinyl)propyl]-3-(4-substituted-benzoyl)-
4-hydroxy-2H-1,2-benzothiazine 1,1-dioxides.
Keywords DSC  Benzothiazine  Thermal analysis 
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Introduction
Sundry benzothiazine derivatives are known to possess a wide
spectrum of biological activities like anti-inflammatory [1],
analgesic and antipyretic [2], antimicrobial [3], antiviral [4],
antitumor [5], antidiabetic [6] and Alzheimer’s and
Parkinson’s disease treatment [7]. Among these, 1,2-benzo-
thiazine 1,1-dioxide nucleus has got considerable attention
after the discovery of 4-hydroxy-2-methyl-2H-1,2-ben-
zothiazine-3-carboxamides 1,1-dioxides (known as oxicams)
as potent anti-inflammatory and analgesic agents.
On the other hand, 1-arylpiperazines represent a poten-
tially biologically active moiety of heterocyclic compounds.
They have been studied as 5-HT1A, 5-HT2A, 5-HT2C, 5-HT3,
5-HT4, 5-HT7 receptors ligands [8–11], a1-adrenoreceptor
antagonists [12] or D2, D3, D4 receptors ligands [13–15].
Some of the well-known antipsychotic drugs that contain
1-arylpiperazine moiety are already available in the market
like buspirone [16], gepirone or ipsapirone [17].
Currently, much research and development is being
focused on the discovery of highly selective dopamine D4
receptor ligands. The reason for the interest in this area
derives from the possible involvement of D4 receptor in
schizophrenia, Parkinson’s disease, bipolar disorder, addi-
tive behaviours, eating disorders such as anorexia nervosa,
bulimia nervosa, binge eating or sexual disorders.
Keeping in view biological activity of benzothiazines in
Alzheimers and Parkinsons diseases and D4 receptors as
potentially target to 1-arylpiperazine derivatives, it was
perceived that synergism of these two bioactive heterocycles
may result in new molecules with accelerated activities.
For this purpose, as continuation our previous investiga-
tion on 1,2-benzothiazine derivatives, we have synthesized a
series of novel 3-substituted-2H-2-{[3-(4-phenyl)-1-piper-
azinyl]-propyl}-4-hydroxy-1,2-benzothiazine 1,1-dioxides.
This new 1,2-benzothiazine 1,1-dioxide derivatives have
some structural similarities with other D4 full or partial
agonist like: WAY-100635 [18], A-412997 [19, 20],
FAUC-316 and FAUC-299, ABT-724 and ABT-670 [21],
which are in pharmacological screening tests.
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On other hand solid form diversity of pharmaceutical
substances may influence the efficacy and safety of drug
products. Physical and chemical characterization of different
solid phases that may occur during crystallization and
pharmaceutical formulation processes, i.e. polymorphs,
pseudopolymorphism, solvates, desolvated solvates and
amorphous materials are advisable for both drugs and
excipients. It is very important to control the crystal form of
the drug during the various stages of drug development,
because any phase changes and change in the degree of
crystallinity can alter the bioavailability of the drug. Thermal
analysis is one of the most frequently used instrumental
techniques on pharmaceutical researches [22–31].
Experimental
Synthesis
Reagents and solvents were purchased from commercial
suppliers and used as received. Dry solvent was obtained
according to the standard procedure. Analytical silica gel 60
F254-coated TLC plates were obtained from Fluka Chemie
Gmbh and were visualized with UV light. Flash column
chromatographic purifications were performed using Sigma-
Aldrich 60A silica gel 230–400 mesh. The proton nuclear
magnetic resonance (1H NMR) spectra were measured on a
Brucker 300 MHz NMR spectrometer. The samples were
prepared by dissolving 5 mg of each form in 600 ll of
CDCl3. Melting points were recorded using MEL-TEMP
capillary melting point apparatus and were uncorrected.
Elemental analyses were performed by Carlo Erba NA 1500
analyser and were within ±0.4 % of the theoretical value.
FTIR spectra were run on a Perkin–Elmer spectrum two
UATR FT-IR spectrometer. The samples were applied as
solids.
General procedure for the preparation of 2-[3-(4-phenyl-1-
piperazinyl)propyl]-3-(4-substituted-benzoyl)-4-hydroxy-
2H-1,2-benzothiazine 1,1-dioxide derivatives
(Fig. 1, Scheme 1)
Procedure A. 2-(4-substituted-phenacyl)-2H-benzisothiazol-
3-on 1,1-dioxides A mixture of commercially available
saccharine (0.92 g, 5 mmol) with 5 mmol of corresponding
2-bromoacetophenone 2a–2d [2-bromoacetophenone for
obtaining 3a, 2-bromo-40-methoxyacetophenone (3b),
2-bromo-40-fluoroacetophenone (3c) and 2,40-dibromoace-
tophenone (3d)] in 7 mL of N,N-dimethylformamide
(DMF) and triethylamine (0.7 mL, 5 mmol) was stirred at
room temperature for 10 h, then poured over ice cooled
water (50 mL) resulted in the formation of a white solid,
which was filtered and washed with cold water. The solid
was dried and recrystallized from ethanol to give 2-(4-
substituted-phenacyl)-2H-benzisothiazol-3-on 1,1-dioxides
with 88.7–98.7 % yield;
3a: Anal. C15H11NO4S (m.w. 301.32); m.p. 472–474 K
(EtOH). 1H NMR d: 5.15 s (2H, CH2), 7.49–7.97 m (9H, ArH).
FT-IR: 1,739 and 1,694 (CO), 1,335 and 1,181 (SO2) cm
-1.
3b: Anal. C16H13NO5S (m.w. 331.34); m.p. 434–436 K
(EtOH). 1H NMR d: 3.89 s (3H, OCH3), 5.11 s (2H, CH2),
6.96–7.97 m (8H, ArH). FT-IR: 1,738 and 1,693 (CO),
1,330 and 1,183 (SO2) cm
-1.
3c: Anal. C15H10FNO4S (m.w. 319.31); m.p. 438–441 K
(EtOH). 1H NMR d: 5.11 s (2H, CH2), 7.16–8.01 m (8H, ArH).
FT-IR: 1,738 and 1,693 (CO), 1,330 and 1,183 (SO2) cm
-1.
3d: Anal. C15H10BrNO4S (m.w. 380.21); m.p. 462–464 K
(EtOH). 1H NMR d: 5.10 s (2H, CH2), 7.66–7.94 m (8H, ArH).
FT-IR: 1,733 and 1,703 (CO), 1,328 and 1,179 (SO2) cm
-1.
Procedure B. Rearrangement of benzisothiazolones 3a–3d
to the corresponding derivatives of 3-(4-substituted-ben-
zoyl)-4-hydroxy-2H-1,2-benzothiazines Three millimoles
of corresponding benzisothiazolone 1,1-dioxide 3a–3d (3a
for obtaining 4a, 3b for 4b, 3c for 4c and 3d for 4d) were
dissolved in 7.5 mL sodium ethoxide (2.3 %) at 313 K C
and stirred with heating to 328–333 K for 5–10 min. Col-
our changes from beige to deep red were observed. After
this time and dissolving all of the substance, the mixture
was rapidly cooled to 298 K and 7.5 mL HCl (9 %) was
added. Colour changed from deep red to deep yellow and
the product precipitated. The solid was filtered off, washed
with cold water, dried and purified by crystallization from
EtOH to give 4a–4d with 83.5–86.4 % yield.
4a: Anal. C15H11NO4S (m.w. 301.32); m.p. 434–436 K
(EtOH). 1H NMR d: 6.07 s (1H, NH), 7.44–8.23 m (9H,
ArH), 15.71 s (1H, OH enolic); FT-IR: 3,262 (NH), 1,594
[C(OH)=C–C(O)], 1,301 and 1,176 (SO2) cm
-1.
4b: Anal. C16H13NO5S (m.w. 331.34); m.p. 450–452 K
(EtOH). 1H NMR d: 3.90 s (3H, OCH3), 6.06 s (1H, NH),
7.27–8.21 m (8H, ArH), 16.02 s (1H, OH enolic). FT-IR:
3,258 (NH), 1,597 [C(OH)=C–C(O)], 1,310 and 1,179
(SO2) cm
-1.
4c: Anal. C15H10FNO4S (m.w. 319.31); m.p. 466–468 K
(EtOH). 1H NMR d : 5.91 s (1H, NH), 7.13–8.20 m (8H,
ArH), 15.80 s (1H, OH enolic). FT-IR: 3,151 (NH), 1,590
[C(OH)=C–C(O)], 1,280 and 1,158 (SO2) cm
-1.
4d: Anal. C15H10BrNO4S (m.w. 380.21); m.p. 511–514 K
(EtOH). 1H NMRd: 6.17 s (1H, NH), 7.27–8.26 m (8H, ArH),
15.73 s (1H, OH enolic). FT-IR: 3,225 (NH), 1,583
[C(OH)=C–C(O)], 1,287 and 1,179 (SO2) cm
-1.
Procedure C. 1-(3-chloropropyl)-4-phenylpiperazine
(Fig. 1, Scheme 2) A commercially available 1-phenyl-
piperazine (6.48 g, 40 mmol) and 1-bromo-3-chloropropane
(4.4 mL, 44 mmol) were dissolved in acetone (12 mL) with
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addition of 25 % NaOH (7 mL), stirred slowly in room
temperature for 8 h and left overnight. After this time ether
(80 mL) was added and stirred further for 30 min. Then, the
mixture was divided in a funnel into two parts. The ether part
was dried with MgSO4 and evaporated in vacuum. The res-
idue was purified by flash silica gel chromatography, eluting
with EtOAc to give 7.62 g (79.8 %) a pale yellow oil of 1-(3-
chloropropyl)-4-phenylpiperazine 5; Anal. C13H19ClN2
(m.w. 238.76); 1H NMR d: 1.95–2.09 m (2H, CH2CH2CH2),
2.53–2.70 m [6H, CH2N(CH2)2], 3.19–3.22 m [4H,
N(CH2)2], 3.61–3.65 t (2H, CH2CH2CH2N-piperazine,
J = 6 Hz), 6.84–7.27 m (5H, ArH).
Procedure D. 3-(4-substituted-benzoyl)-2-[3-(4-phenyl-
1-piperazinyl)propyl]-4-hydroxy-2H-1,2-benzothiazine 1,
1-dioxide derivatives To the stirred mixture of 5 mmol of
corresponding 1,2-benzothiazine 4a–4d in 20 mL of anhy-
drous EtOH was added 5 mL of EtONa (prepared from
0.115 g of Na and 5 mL of anhydrous EtOH). Then, 5 mmol
of 1-(3-chloropropyl)-4-phenylpiperazine 5 was added and
refluxed with stirring for 10–12 h. When the reaction was
ended, which was controlled on TLC plates, ethanol was
distiled off, the residue was treated with 50 mL of CHCl3
and insoluble materials were filtered off. The filtrate was
then evaporated and the residue was purified by crystalliza-
tion from ethanol to give 6a–6d (yield: 34.0–54.0 %).
2-[3-(4-phenyl-1-piperazinyl)propyl]-3-benzoyl-4-hydroxy-
2H-1,2-benzothiazine 1,1-dioxide (6a). Anal. C28H29N3O4S
(m.w. 503.61); m.p. 440–443 K (EtOH). 1H NMR d:
1.21–1.26 m (2H, CH2CH2CH2), 1.94–1.99 m (2H, CH2CH2
CH2N-piperazine), 2.21–2.28 m [4H, N(CH2)2], 3.01–3.27 m
[6H, CH2N(CH2)2], 6.82–8.22 m (14H, ArH), 15.71 s (1H, OH
enolic); FT-IR: 1,598, 1,611 [C(OH)=C–C(O)], 1,331 and 1,173
(SO2) cm
-1; Anal. Calcd: C, 66.78; H, 5.80; N, 8.34. Found: C,
66.66; H, 5.94; N, 8.39.
2-[3-(4-phenyl-1-piperazinyl)propyl]-3-(4-methoxyben-
zoyl)-4-hydroxy-2H-1,2-benzothiazine 1,1-dioxide (6b).
Anal. C29H31N3O5S (m.w. 533.64); m.p. 388–391 K
(EtOH). 1H NMR d: 1.22–1.31 m (2H, CH2CH2CH2),
1.96–1.98 m (2H, CH2CH2CH2N-piperazine), 2.24–2.30 m
[4H, N(CH2)2], 3.01–3.35 m [6H, CH2N(CH2)2], 3.90 s (3H,
OCH3), 6.85–8.20 m (13H, ArH), 15.76 s (1H, OH enolic);
FT-IR: 1,599, 1,612 [C(OH)=C–C(O)], 1,318 and 1,173
(SO2) cm
-1; Anal. Calcd: C, 65.24; H, 5.85; N, 7.91. Found:
C, 65.54; H, 5.90; N, 8.00.
2-[3-(4-phenyl-1-piperazinyl)propyl]-3-(4-fluorobenzoyl)-
4-hydroxy-2H-1,2-benzothiazine 1,1-dioxide (6c). Anal.
C28H28FN3O4S (m.w. 521.60); m.p. 376–378 K (EtOH).
1H
NMR d: 1.21–1.26 m (2H, CH2CH2CH2), 1.95–2.00 m (2H,
CH2CH2CH2N-piperazine), 2.26 s [4H, N(CH2)2],
3.04–3.30 m [6H, CH2N(CH2)2], 6.82–8.20 m (13H, ArH),
15.50 s (1H, OH enolic); FT-IR: 1,597, 1,609 [C(OH)=
C–C(O)], 1,333 and 1,174 (SO2) cm
-1; Anal. Calcd: C,
64.47; H, 5.41; N, 8.06. Found: C, 64.35; H, 5.44; N, 8.02.
2-[3-(4-phenyl-1-piperazinyl)propyl]-3-(4-bromobenzoyl)-
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BrN3O4S (m.w. 582.51); m.p. 374–377 K (EtOH).
1H NMR
d: 1.22–1.26 m (2H, CH2CH2CH2), 1.97–2.07 m (2H,
CH2CH2CH2N-piperazine), 2.24–2.34 m [4H, N(CH2)2],
3.03–3.31 m [6H, CH2N(CH2)2], 6.86–8.19 m (13H, ArH),
15.70 s (1H, OH enolic); FT-IR: 1,599, 1,610 [C(OH)
=C–C(O)], 1,328 and 1,173 (SO2) cm
-1; Anal. Calcd: C,
57.71; H, 4.84; N, 7.24. Found: C, 57.32; H, 4.85; N, 7.22
Differential thermal analysis
The DSC traces were recorded on a Mettler Toledo
DCS 25 measuring cell with TC15TA Controller, cali-
brated with indium to ensure the accuracy of the calori-
metric scale. Samples weighing 6–10 mg (crystals form)
were characterized in sealed 40 ll aluminium pans with
lids and subjected to thermal analysis under a flowing
argon atmosphere (30 cm3 min-1). Analysis was carried
out from 303 K using heating rate 5 K min-1 (additionally
1 and 10 K min-1) with an identical empty sample pan as
reference. For each compound several measurements were
performed. Melting temperatures were determined by the
onset because the onset temperature is independent of
sample mass and scanning rate. Pans with lids and samples
were weighed both before and after the experiment. In all
cases, the mass was identical.
Computational methods
The primary task for the computational work was to
determine the optimized geometry of the compounds.
Calculations were carried out using the GAUSSIAN 09
software package [32]. Density functional theoretical
(DFT) computations were performed using the closed shell
Becke–Lee–Yang–Parr hybrid exchange–correlation three-
parameter functional (B3LYP) [33–35] in combination
with 6-311?G(d,p) basis set. Harmonic vibrational wave-
numbers were calculated using analytic second derivatives
to confirm the convergence to minima in the potential
surface. The absence of imaginary frequency modes for the
optimized structures confirm a true minimum on the
potential energy surface. All calculations were carried out
in vacuum.
Results and discussion
The DSC scans for benzisothiazolones 3a–3d are shown in
Fig. 2. For all compounds only one endothermic effect,
corresponds to the melting, is observed. The melting points
were found as 470 K (3a), 440 K (3b), 439 K (3c), 466 K
(3d). The peaks are sharp and symmetrical, characteristic
for a pure substance.
The DSC scans for derivatives of 3-(4-substituted-ben-
zoyl)-4-hydroxy-2H-1,2-benzothiazines 4a–4d are given in
Fig. 3. For compound 4a two endothermic effects were
detected. The DSC signal starts to fall below the baseline at
428 K. The second peak is symmetrical. The onset tem-
perature is 428 K. For compound 4b the DSC trace shows a
wide endothermic effect with a small bend at 452 K. For
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Fig. 2 DSC curves for
compounds 3a–3d heated at
5 K min-1
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The peak is wide and asymmetric. For compound 4c signal
starts to fall below the baseline at 460 K and then rapidly at
460 K. For compound 4d a small bend at 504 K is
observed. For these substances, DSC runs show the pres-
ence of overlapping peaks, corresponding probably to two
thermal events, close to each other. In order to determine
the overlapping peak positions and areas, a curve fitting
analysis for DSC curves was carried out. Deconvolved
signal was calculated using Exponentially Modified
Gaussian function (EMG, r2 = 0.991, 0.973, 0.982 for 4b,
4c, 4d, respectively). As a result two separate peaks were
obtained (Fig. 3). The onset temperatures are: 450 and
453 K for 4b, 464 and 468 K for 4c, 499 and 505 K for 4d.
The DSC scans for 3-(4-substituted-benzoyl)-2-[3-(4-
phenyl-1-piperazinyl)propyl]-4-hydroxy-2H-1,2-benzothi-
azine 1,1-dioxide derivatives 6a–6d are presented in Fig. 4.
For compound 6a, the DSC trace shows a wide endother-
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Fig. 3 DSC curves for
compounds 4a–4d heated at
5 K min-1 (solid line) and
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Fig. 4 DSC curves for
compounds 6a–6d heated at
5 K min-1 (solid line) and
deconvolved signal (dash line)
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two separate peaks were obtained. The onset temperatures
are: 435 and 441 K (r2 = 0.997). For compound 6b one
endothermic effect was detected. It is wide, with a small
step at temperature 385 K. This effect is better to observe
on the curves with scanning rate 10 K min-1. The onset
temperatures after deconvolved are 385 and 391 K
(r2 = 0.999). Two endothermic effects were observed
during heating substance 6c. The first with maximum at
359 K starts at 352 K. The second one is wide and
asymmetric. This effect shows the presence of overlapping
peaks, corresponding to two thermal events. The onset
temperatures after deconvolved are 377 and 383 K
(r2 = 0.971). Three thermal effects are detected heating
substance 6d. Two endothermic peaks at 374 and 428 K
and wide exothermic one. It starts at 398 K and end at
423 K. The second endothermic peak is sharp and sym-
metrical, characteristic for melting process. The first one is

















Fig. 5 Three possible
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Fig. 6 Experimental FTIR spectrum for compounds 6a–6d
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After deconvolved two separate peaks were obtained. The
onset temperatures are: 372 and 377 K (r2 = 0.981).
The experiments for heating and cooling rates were also
performed. In addition, second heating run, after rapid
cooling, was carried out. For all experiments, thermal
effects were not observed. This indicate that thermal events
are irreversible. After the melting process, substances go
into the amorphous state.
We suggest that the presence of overlapping peaks, close to
each other, is the result of dynamic proton tautomerism in
their crystal structures. Three isomers are possible: enol–keto,
keto–enol and keto–keto form (Fig. 5). However, crystalline
state may be stabilized by strong intermolecular O–HO
hydrogen bonding and keto–keto form, probably is not pres-
ent. These conditions were detected in crystal structure sim-
ilar compounds: 3-[hydroxy(phenyl)methyl]-2,5,7-trimethyl-
2,3-dihydropyrido[3,2-e]-[1, 2]thiazin-4-one 1,1-dioxide and
3-(1-hydroxyethylidene)-2,5,7-trimethyl-2,3-dihydropyri-
do[3,2-e][1, 2]-thiazin-4-one 1,1-dioxide [36].
The FTIR spectra of compounds 6a–6d in the solid-state is
shown in Fig. 6. In the region 3,900–1,800 cm-1, only a weak
and broad bands are observed. It was assigned to stretching
vibration of the hydroxyl group involved in the intra- and
intermolecular hydrogen bond, which is superimposed on the
C–H and Ar–H stretching vibration. A few small maximums
were detected. By comparing FTIR spectra in this region, the
sharpness and intensity of bands seem to indicate that H bonds
are not as strong in 6c and 6d as they are in 6a and 6b. In
addition, for substance 6c and 6d, weak and broad bands at
3,380, 3,670 cm-1 (6c) and 3,411, 3,723 cm-1 (6d) were
detected. This can be probably assigned to intermolecular
halogen bonding (interaction). In the region 1,800–450 cm-1,
FTIR spectra for 6a–6d is similar. Single stretching band
characteristic for C=O vibration is not observed. The band
with a higher intensity near 1,600 cm-1. It was assigned to
stretching vibration of C(OH)=C–C(O). It splits into two
bands at 1,598, 1,611 cm-1 (6a), 1,599, 1,612 cm-1 (6b),
1,597, 1,609 cm-1 (6c), 1,599, 1,610 cm-1 (6d) since the
C=O group is engaged in hydrogen bonding.
The main absorption bands of FTIR theoretical and
experimental were compared and shown in Table 1. The
calculated vibrational wavenumbers are in good agreement
with the experimental data expect vibration of C(OH)=
C–C(O). But the calculations were performed for single
molecules in the gas phase. The significant differences may
indicate the hydrogen bonding in the solid-state.
Dynamic proton transfer may cause small differences in
molecular packing and possibility co-existence in a crys-
talline state two tautomeric forms: keto–enol cannot be
precluded. Thus, on the DSC curves, overlapping peaks,
close to each are observed. Our theoretical calculations
show small differences in the energy between both forms
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(6a–6d). Thus, the populations of the tautomers keto–enol
in vacuum estimated using Boltzmann distribution are in
the approximate ratio 0.55:0.45 for 4a–4d and 0.52:0.48 for
6a–6d. The results of theoretical calculations show also
that third possible tautomeric form, keto–keto, is the most
stable form. However, as already mentioned, ability to
form hydrogen bonds stabilize the crystal structure.
The molecular electrostatic potential (MEP) is helpful in
identifying sites for intra- and intermolecular interactions
[37]. In drug-receptor, it is a very useful descriptor in
understanding sites for electrophilic and nucleophilic
reactions as well as hydrogen bonding interactions [38].
The calculated MEP for compound 4c is shown in Fig. 7.
Similar results were obtained for other molecules. Negative
regions (red and yellow) are found around the S=O groups,
–F atom in benzene ring and also close to O atom at –OH
and –CO group. Our theoretical calculations for the dimer
interaction through the hydrogen bond show a stabilizing
effect. The energy of interaction is higher for molecule 6a
and 6b. Energy value obtained for molecule 6c and 6d are
lower by 2 kJ mol-1. It is worth noting that the enthalpy of
melting is also the highest for substance 6a and the lower
for substance 6d.
The DSC traces for compound 6c and 6d are different
from the trace for compound 6a and 6b. An additional
thermal effect is observed. The presence of the –Br and –F
substituent in the benzene ring causes a strong inductive
effect. Electrons are withdrawn from the ring through a r
bond. This may facilitate intermolecular O–HF bond
formation. It also seems that an important factor affecting
the strong of intermolecular O–HO–S hydrogen bond is a
propyl-4-phenylpiperazine group (spherical barrier). As a
consequence, co-existence in crystalline state forms with
differences in molecular packing is possible (three peaks
on DSC traces for 6c). On other hand a resonance effect
(donation of electrons through a p bond) increases p
electron density. It can influence the van der Waal’s
interactions between benzene rings. Compound 6d shows
two melting peaks with a recrystallization step. On heating,
the substance is not directly transformed from crystalline
state to an isotropic melt. The second melting peak corre-




ides were synthesized. The studied compounds are interesting
materials due to their potential biologically active. Thermal
analysis may be very useful for monitoring and identification
substances during organic synthesis. In pharmaceutical
industry, it is very important to control the purity of crystal
form. The important aspect of our investigation was to
determine the existence of multiple crystal forms. The DSC
scans for all compounds show more than one endothermic
effect (or overlapping peaks), which might suggest dynamic
proton transfer between two or three possible tautomeric
forms: O-keto/O-enol, O-enol/O-keto and O-keto/O-keto/
CH2 in crystals 2-[3-(4-phenyl-1-piperazinyl)propyl]-3-
(4-substituted-benzoyl)-4-hydroxy-2H-1,2-benzothiazine 1,
1-dioxides. The study further demonstrates the utility of
deconvolution software for separating overlapping DSC en-
dotherms. Our theoretical calculations show small differences
in the energy between keto–enol tautomeric forms. The FTIR
spectra analysis and theoretical calculations suggest that the
crystal state is stabilized by a strong intermolecular hydrogen
bonding. The presence of the –Br and –F substituent in the
benzene ring causes an inductive effect. As a consequence, co-
existence in crystalline state forms with differences in
molecular packing is possible.
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